Baseline Characteristic Of Participants In The Victor (Vericiguat Global Study In Participants With Chronic Heart Failure) Trial Global Study In Participants With Chronic Heart Failure) Trial:
Faiez Zannad(Centre Hospitalier Régional et Universitaire de Nancy), Javed Butler(Jackson Memorial Hospital), Kevin Anstrom(PragmatIC (United Kingdom)), Yogesh N.V. Reddy(Mayo Clinic), Ciaran J. McMullan(Harvard University), Robert J. Mentz(Duke University), James E. Udelson(Tufts Medical Center), Marc P. Bonaca(The Medical Center of Aurora), Eldrin Lewis(Stanford Health Care), Michele Senni(The Medical Center of Aurora), Adriaan A. Voors(The Medical Center of Aurora), Carolyn Lam(National University of Singapore), Mahesh J. Patel, Aiwen Xing(Merck & Co., Inc., Rahway, NJ, USA (United States)), Piotr Ponikowski(The Medical Center of Aurora), Giuseppe Rosano(Università degli studi di Cassino e del Lazio Meridionale), JoAnn Lindenfeld(Vanderbilt University Medical Center), Christopher O’Connor(Duke University), Davis Gates(Merck & Co., Inc., Rahway, NJ, USA (United States)), Justin A. Ezekowitz(University of Alberta), Clara Ines Saldarriage-Giraldo(The Medical Center of Aurora), Stefano Corda(Université Paris Cité)
Cited by 0
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Journal of Heart Failure|2022|2.1k